Image 2_Case report: Significant lesion reduction and neural structural changes following ibogaine treatments for multiple sclerosis.jpeg by David Qixiang Chen (8198265)

“…Ibogaine, a psychoactive alkaloid, has been proposed as a potential neuroregenerative agent due to its multifaceted pharmacological profile. We present two case studies of MS patients who underwent a novel ibogaine treatment, highlighting significant neuroimaging changes and clinical improvements. …”

Image 1_Case report: Significant lesion reduction and neural structural changes following ibogaine treatments for multiple sclerosis.jpeg by David Qixiang Chen (8198265)

“…Ibogaine, a psychoactive alkaloid, has been proposed as a potential neuroregenerative agent due to its multifaceted pharmacological profile. We present two case studies of MS patients who underwent a novel ibogaine treatment, highlighting significant neuroimaging changes and clinical improvements. …”

Summary of measured parameters. by Aaron L. Sayler (19797446)

“…Male KO mice also displayed a significant decrease in rearing activity and blood pressure. …”

Raw data. by Aaron L. Sayler (19797446)

“…Male KO mice also displayed a significant decrease in rearing activity and blood pressure. …”

S1 Graphical abstract - by Aman Goyal (19231397)

“…</p><p>Conclusions</p><p>Our analysis showed a significant decrease in mortality from paroxysmal tachycardia since 1999, although there has been a slight increase in recent years. …”

Sexual maturity status of female C57BL/6J Mice at different ages. by Yan She (8639796)

DataSheet1_Significant nocturnal wakefulness after sleep onset in metabolic dysfunction–associated steatotic liver disease.PDF by Sofia Schaeffer (20379954)

“…Further, data from sleep questionnaires proved sleep-wake disruption in patients with MASLD. We objectively assessed sleep-wake rhythms in patients with biopsy-proven MASLD (n = 35) and healthy controls (HC, n = 16) using actigraphy 24/7 for 4 weeks. …”

DataSheet3_Significant nocturnal wakefulness after sleep onset in metabolic dysfunction–associated steatotic liver disease.PDF by Sofia Schaeffer (20379954)

“…Further, data from sleep questionnaires proved sleep-wake disruption in patients with MASLD. We objectively assessed sleep-wake rhythms in patients with biopsy-proven MASLD (n = 35) and healthy controls (HC, n = 16) using actigraphy 24/7 for 4 weeks. …”

DataSheet2_Significant nocturnal wakefulness after sleep onset in metabolic dysfunction–associated steatotic liver disease.PDF by Sofia Schaeffer (20379954)

“…Further, data from sleep questionnaires proved sleep-wake disruption in patients with MASLD. We objectively assessed sleep-wake rhythms in patients with biopsy-proven MASLD (n = 35) and healthy controls (HC, n = 16) using actigraphy 24/7 for 4 weeks. …”

DataSheet4_Significant nocturnal wakefulness after sleep onset in metabolic dysfunction–associated steatotic liver disease.PDF by Sofia Schaeffer (20379954)

“…Further, data from sleep questionnaires proved sleep-wake disruption in patients with MASLD. We objectively assessed sleep-wake rhythms in patients with biopsy-proven MASLD (n = 35) and healthy controls (HC, n = 16) using actigraphy 24/7 for 4 weeks. …”

Expression profile of WRKY-TFs and ROS accumulation in susceptible T200 and tolerant TME3 cassava genotypes. by Bulelani L. Sizani (21485746)

Transcript levels of MAPK, NIK, NLR and SA-depended gene pathways and responsive genes. by Bulelani L. Sizani (21485746)

Prediction of bacterial BugBase phenotype. by Jun Sun (48981)

Transcript levels of MAPK, NIK, NLR and SA-dependent gene pathways and responsive genes. by Bulelani L. Sizani (21485746)

South African cassava mosaic virus (SACMV) genome structure and the effect of SACMV on cassava leaf symptoms. by Bulelani L. Sizani (21485746)

Fig 5 - by Wardah K. Mustahsan (17484456)

Supporting information – data for plots. by Maria Nadinskaia (22662419)

Non-enzymatic antioxidants in hemolymph of honey bee workers. by Agnieszka Murawska (11021928)

Enzymes activity in hemolymph of honey bee workers. by Agnieszka Murawska (11021928)

Renal outcomes of both treatment groups. by Marwan El-Deyarbi (21688492)

“…Participants in the multifactorial group achieved a significant mean difference in low-density lipoprotein cholesterol levels (mean difference = −0.14, 95% CI: −0.27–0.001, P < 0.03), and significant adjusted mean difference of eGFR levels difference (3.93 mL/min/1.73 m², 95% CI: 1.27–6.58, P < 0.01) at study completion compared to those in the control group. …”